Barton A C, Black L E, Sibley D R
Experimental Therapeutics Branch, National Institute for Neurological Disorders and Stroke, Bethesda, Maryland 20892.
Mol Pharmacol. 1991 May;39(5):650-8.
Y-79 human retinoblastoma cells can be induced to express significant quantities of functional D2 dopamine receptors after attachment and differentiation with sodium butyrate. In membranes prepared from differentiated Y-79 cells, the D2 dopaminergic antagonist [3H] methylspiperone exhibits a KD of 77 pm and a Bmax of 60 fmol/mg of protein, whereas the antagonist [125I]iodosulpride reveals a KD of 0.77 nM and a Bmax of 40 fmol/mg of protein. Dopamine also induces a pharmacologically specific, pertussis toxin-sensitive, dose-dependent inhibition of forskolin-stimulated adenylyl cyclase activity, with an EC50 of 2 microM and a maximal response at 100 microM (approximately 50% enzyme inhibition). Pretreatment of the cells with dopamine results in a diminution in the subsequent ability of dopamine to inhibit adenylyl cyclase activity. This effect is time dependent, reaching maximal desensitization after approximately 24 hr. The dopamine dose-response curve for inducing desensitization exhibits an EC50 of approximately 2-3 microM and a maximal response at approximately 0.1-1 mM, similar to that for inhibiting adenylyl cyclase activity. After maximal desensitization, the EC50 for dopamine-induced inhibition of adenylyl cyclase activity is increased greater than 20 fold (lower affinity) and the maximum inhibition is decreased to approximately 15%, representing an approximately 70% desensitization. The agonist-induced desensitization is pharmacologically specific, inasmuch as preincubation of the cells with the dopaminergic agonists epinine and (+-)-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene or the D2-selective agonist N-0434 also results in desensitization of dopamine-induced inhibition of enzyme activity, whereas preincubation with the D1-selective agonist SKF-38393 or with the nondopaminergic agonists isoproterenol and serotonin results in little or no desensitization. Preincubation of the cells with dopamine also promotes a time-dependent increase (approximately 3-fold) in the KD for [3H]methylspiperone, with no change in its Bmax. In contrast, after dopamine preincubation, the KD for [125I]iodosulpride is unchanged, whereas its Bmax is reduced by approximately 50% upon maximum desensitization. In addition, agonist pretreatment promotes a functional uncoupling of the D2 receptor, as suggested by a loss of high affinity agonist binding observed in radioligand competition binding assays after desensitization. Upon removal of agonist, the cellular D2 receptor binding activity and functional response recover to control levels within a 24-hr period. These results suggest that prolonged exposure of cells to dopaminergic agonists initiates a desensitization process involving a functional uncoupling of the D2 dopamine receptor as well as a loss of its ligand binding activity.
Y-79人视网膜母细胞瘤细胞在与丁酸钠贴壁并分化后,可被诱导表达大量功能性D2多巴胺受体。在由分化的Y-79细胞制备的膜中,D2多巴胺能拮抗剂[3H]甲基螺哌隆的KD为77皮摩尔,Bmax为60飞摩尔/毫克蛋白质,而拮抗剂[125I]碘舒必利的KD为0.77纳摩尔,Bmax为40飞摩尔/毫克蛋白质。多巴胺还可诱导对福司可林刺激的腺苷酸环化酶活性产生药理学特异性的、百日咳毒素敏感的、剂量依赖性抑制,EC50为2微摩尔,在100微摩尔时出现最大反应(约50%的酶抑制)。用多巴胺预处理细胞会导致多巴胺随后抑制腺苷酸环化酶活性的能力降低。这种效应是时间依赖性的,大约24小时后达到最大脱敏。诱导脱敏的多巴胺剂量反应曲线的EC50约为2 - 3微摩尔,在约0.1 - 1毫摩尔时出现最大反应,类似于抑制腺苷酸环化酶活性的情况。在最大脱敏后,多巴胺诱导的腺苷酸环化酶活性抑制的EC50增加超过20倍(亲和力降低),最大抑制降至约15%,代表约70%的脱敏。激动剂诱导的脱敏在药理学上具有特异性,因为用多巴胺能激动剂去甲肾上腺素和(±)-2-氨基-6,7-二羟基-1,2,3,4-四氢萘或D2选择性激动剂N-0434预孵育细胞也会导致多巴胺诱导的酶活性抑制脱敏,而用D1选择性激动剂SKF-38393或非多巴胺能激动剂异丙肾上腺素和5-羟色胺预孵育则导致很少或没有脱敏。用多巴胺预孵育细胞还会促进[3H]甲基螺哌隆的KD随时间依赖性增加(约3倍),而其Bmax不变。相反,多巴胺预孵育后,[125I]碘舒必利的KD不变,而其Bmax在最大脱敏时降低约50%。此外,激动剂预处理促进了D2受体的功能性解偶联,这在脱敏后放射性配体竞争结合试验中观察到的高亲和力激动剂结合丧失中得到提示。去除激动剂后,细胞D2受体结合活性和功能反应在24小时内恢复到对照水平。这些结果表明,细胞长时间暴露于多巴胺能激动剂会启动一个脱敏过程,涉及D2多巴胺受体的功能性解偶联及其配体结合活性的丧失。